The 2nd PhIII schizophrenia study for Intra-Cellular drug is a disaster, shares shredded
A year after turning up some mixed schizophrenia data from their first late-stage study of their lead drug for schizophrenia, Intra-Cellular Therapeutics today said that the second late-stage trial was a near complete flop.
As in many similar studies, Intra-Cellular $ITCI says their psychiatric drug was done in by a high placebo response. And like many others, it is vowing to remain committed to the development program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.